2001
DOI: 10.1053/ajkd.2000.22466
|View full text |Cite
|
Sign up to set email alerts
|

Tissue Plasminogen Activator Use in Maintaining Patency in Hemodialysis Access Catheters

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2005
2005
2005
2005

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…3 The majority of HD units have established protocols that use either alteplase (TPA) or reteplase in dwell times ranging from 2 to 96 hr as empiric treatment for CD owing to suspected thrombus. There is some evidence [3][4][5][6][7][8][9][10][11] to support the use of TPA in CD; however, there are no studies that address the optimal dwell time. As such, there are no guidelines regarding dwell time published.…”
Section: Introductionmentioning
confidence: 99%
“…3 The majority of HD units have established protocols that use either alteplase (TPA) or reteplase in dwell times ranging from 2 to 96 hr as empiric treatment for CD owing to suspected thrombus. There is some evidence [3][4][5][6][7][8][9][10][11] to support the use of TPA in CD; however, there are no studies that address the optimal dwell time. As such, there are no guidelines regarding dwell time published.…”
Section: Introductionmentioning
confidence: 99%